A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (NCT06706622)

🧪 Interventions in This Study

• Amlenetug (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (74 Sites)

Showing the first 25 of 74 sites.

• Mayo Clinic — Scottsdale, Arizona
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• University of California, San Francisco Neurosciences Clinical Research Unit — San Francisco, California
• CenExel Rocky Mountain Clinical Research, LLC — Englewood, Colorado
• Yale New Haven Health — North Haven, Connecticut
• Parkinson's Disease And Movement Disorder Center Of Boca Raton — Boca Raton, Florida
• University of Florida Norman Fixel Institute for Neurological Diseases — Gainesville, Florida
• Indiana Health University — Indianapolis, Indiana
• Johns Hopkins University School of Medicine — Baltimore, Maryland
• Brigham and Women's Hospital — Boston, Massachusetts
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• QUEST Research Institute — Farmington Hills, Michigan
• Mayo Clinic — Rochester, Minnesota
• University Nebraska Medical Center — Omaha, Nebraska
• NYU Medical Center - Dysautonomia center — New York, New York
• Columbia University Medical Center - The Neurological Institute of New York — New York, New York
• Cleveland Clinic - Neurological Institute — Cleveland, Ohio
• University of Pennsylvania — Philadelphia, Pennsylvania
• University Of Pittsburgh — Pittsburgh, Pennsylvania
• Vanderbilt University Medical Center-Cognitive and Movement Disorders Group — Nashville, Tennessee
• University of Texas Southwestern Medical Center ¿ Multiple System Atrophy Clinic — Dallas, Texas
• Baylor College Of Medicine — Houston, Texas
• Inland Northwest Research — Spokane, Washington
• Liverpool Hospital - South Western Sydney Local Health District — Liverpool, New South Wales
• Westmead Hospital — Westmead, New South Wales

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple System Atrophy

• Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy — Rochester, Minnesota
• A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy — Los Angeles, California
• A Study of Lu AF82422 in Participants With Multiple System Atrophy — Fountain Valley, California
• GDNF Gene Therapy for Multiple System Atrophy — Irvine, California
• Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic — Nashville, Tennessee

Explore by condition: All Multiple System Atrophy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.